Immunocore is the world’s leading TCR (T cell receptor) company focused on delivering first-in-class biologics that transform lives. The Company’s therapeutics have broad applicability across a wide range of indications, including solid tumours and infectious diseases, and can access a far wider range of targets than typical antibody-based therapies. Its ImmTAC technology enables circulating T cells to selectively identify and kill diseased cells with ultra-high specificity and potency and reduced toxicity.  



  • Lead candidate IMCgp100 in pivotal clinical studies as a monotherapy for patients with metastatic melanoma
  • Bill and Melinda Gates Foundation investment of $40 million for collaboration in infectious diseases in 2016
  • Europe’s largest ever private financing round in biotech with a raise of $320 million in 2015


Europe’s largest ever private financing round in biotech


Our strategy

  • Detailed review and overhaul of all corporate materials, including key messages and creation of a corporate video
  • Extensive programme of media introductions in the weeks before the fundraise announcement in 2015, ensuring that key journalists knew the Company well
  • Communicating Immunocore’s scientific story more broadly, particularly in the run-up to the publication of key scientific data in 2017, including compelling single-agent efficacy of IMCgp100 in a solid, ‘cold’, low mutation tumour



  • Placement of Series A fundraise news, under embargo, yielding worldwide coverage including Financial Times, WSJ, New York Times, newswires and international trade press
  • Momentum continued with ongoing interest in Immunocore’s scientific programme and widespread coverage of corporate development and data during 2016 and 2017